Varicella Zoster Virus Immune Evasion Strategies

  • Allison AbendrothEmail author
  • Paul R. Kinchington
  • Barry Slobedman
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 342)


The capacity of varicella zoster virus (VZV) to cause varicella (chickenpox) relies upon multiple steps, beginning with inoculation of the host at mucosal sites with infectious virus in respiratory droplets. Despite the presence of a powerful immune defense system, this virus is able to disseminate from the site of initial infection to multiple sites, resulting in the emergence of distinctive cutaneous vesiculopustular lesions. Most recently, it has been proposed that the steps leading to cutaneous infection include VZV infecting human tonsillar CD4+ T cells that express skin homing markers that allow them to transport VZV directly from the lymph node to the skin during the primary viremia. It has also been proposed that dendritic cells (DC) of the respiratory mucosa may be among the first cells to encounter VZV and these cells may transport virus to the draining lymph node. These various virus-host cell interactions would all need to occur in the face of an intact host immune response for the virus to successfully cause disease. Significantly, following primary exposure to VZV, there is a prolonged incubation period before emergence of skin lesions, during which time the adaptive immune response is delayed. For these reasons, it has been proposed that VZV must encode functions which benefit the virus by evading the immune response. This chapter will review the diverse array of immunomodulatory mechanisms identified to date that VZV has evolved to at least transiently limit immune recognition.


Migration Attenuation Interferon Biron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



AA and BS were supported by NHMRC grant 457356. PRK acknowledges support for this work by Public Health Service NIH grants NS064022 and EY08098, and funds from the Research to Prevent Blindness Inc. and the Eye and Ear Institute of Pittsburgh.


  1. Abendroth A, Arvin A (1999) Varicella-zoster virus immune evasion. Immunol Rev 168:143–156PubMedCrossRefGoogle Scholar
  2. Abendroth A, Arvin AM (2001) Immune evasion as a pathogenic mechanism of varicella zoster virus. Semin Immunol 13:27–39PubMedCrossRefGoogle Scholar
  3. Abendroth A, Slobedman B, Lee E, Mellins E, Wallace M, Arvin AM (2000) Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol 74:1900–1907PubMedCrossRefGoogle Scholar
  4. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM (2001a) Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol 75:4878–4888PubMedCrossRefGoogle Scholar
  5. Abendroth A, Morrow G, Cunningham AL, Slobedman B (2001b) Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host. J Virol 75:6183–6192PubMedCrossRefGoogle Scholar
  6. Ahn K, Meyer TH, Uebel S, Sempe P, Djaballah H, Yang Y, Peterson PA, Fruh K, Tampe R (1996) Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J 15:3247–3255PubMedGoogle Scholar
  7. Ambagala AP, Cohen JI (2007) Varicella-zoster virus IE63, a major viral latency protein, is required to inhibit the alpha interferon-induced antiviral response. J Virol 81:7844–7851PubMedCrossRefGoogle Scholar
  8. Arvin A (2001) Varicella zoster virus. In: Knipe DaHP (ed) Fields virology, vol 2, 4th edn. Lippincott Williams and Wilkins, Philadelphia, pp 2731–2767Google Scholar
  9. Arvin AM, Schmidt NJ, Cantell K, Merigan TC (1982) Alpha interferon administration to infants with congenital rubella. Antimicrob Agents Chemother 21:259–261PubMedCrossRefGoogle Scholar
  10. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK (1986) Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 154:422–429PubMedCrossRefGoogle Scholar
  11. Arvin AM, Moffat JF, Redman R (1996) Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv Virus Res 46:263–309PubMedCrossRefGoogle Scholar
  12. Balachandra K, Thawaranantha D, Ayuthaya PI, Bhumisawasdi J, Shiraki K, Yamanishi K (1994) Effects of human alpha, beta and gamma interferons on varicella zoster virus in vitro. Southeast Asian J Trop Med Public Health 25:252–257PubMedGoogle Scholar
  13. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252PubMedCrossRefGoogle Scholar
  14. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811PubMedCrossRefGoogle Scholar
  15. Black AP, Jones L, Malavige GN, Ogg GS (2009) Immune evasion during varicella zoster virus infection of keratinocytes. Clin Exp Dermatol 34(8):941–944Google Scholar
  16. Bowden RA, Levin MJ, Giller RH, Tubergen DG, Hayward AR (1985) Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients. Clin Exp Immunol 60:387–395PubMedGoogle Scholar
  17. Cohen JI (1998) Infection of cells with varicella-zoster virus down-regulates surface expression of class I major histocompatibility complex antigens. J Infect Dis 177:1390–1393PubMedCrossRefGoogle Scholar
  18. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D (1999) The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10:661–671PubMedCrossRefGoogle Scholar
  19. Colamonici OR, Domanski P (1993) Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21. J Biol Chem 268:10895–10899PubMedGoogle Scholar
  20. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, Ault KA, Gimbrone MA Jr, Strominger JL, Pober JS (1984) Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA 81:4917–4921PubMedCrossRefGoogle Scholar
  21. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5:1219–1226PubMedCrossRefGoogle Scholar
  22. Desloges N, Rahaus M, Wolff MH (2005) Role of the protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon. J Gen Virol 86:1–6PubMedCrossRefGoogle Scholar
  23. Eisfeld AJ, Yee MB, Erazo A, Abendroth A, Kinchington PR (2007) Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and -independent mechanisms. J Virol 81:9034–9049PubMedCrossRefGoogle Scholar
  24. El Mjiyad N, Bontems S, Gloire G, Horion J, Vandevenne P, Dejardin E, Piette J, Sadzot-Delvaux C (2007) Varicella-zoster virus modulates NF-kappaB recruitment on selected cellular promoters. J Virol 81:13092–13104PubMedCrossRefGoogle Scholar
  25. Erazo A, Kinchington PR (2009) Varicella-zoster virus open reading frame 66 protein kinase and its relationship to alphaherpesvirus US3 kinases. Curr Top Microbiol Immunol, DOI 10.1007/82_2009_7Google Scholar
  26. Farrell HE, Davis-Poynter NJ (1998) From sabotage to camouflage: viral evasion of cytotoxic T lymphocyte and natural killer cell-mediated immunity. Semin Cell Dev Biol 9:369–378PubMedCrossRefGoogle Scholar
  27. Garcia-Sastre A, Biron CA (2006) Type 1 interferons and the virus–host relationship: a lesson in detente. Science 312:879–882PubMedCrossRefGoogle Scholar
  28. Gerlini G, Mariotti G, Bianchi B, Pimpinelli N (2006) Massive recruitment of type I interferon producing plasmacytoid dendritic cells in varicella skin lesions. J Invest Dermatol 126:507–509PubMedCrossRefGoogle Scholar
  29. Gershon AA, Mervish N, LaRussa P, Steinberg S, Lo SH, Hodes D, Fikrig S, Bonagura V, Bakshi S (1997) Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 176:1496–1500PubMedCrossRefGoogle Scholar
  30. Ghosh S, Hayden MS (2008) New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8:837–848PubMedCrossRefGoogle Scholar
  31. Grose C (1981) Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics 68:735–737PubMedGoogle Scholar
  32. Haller O, Kochs G, Weber F (2006) The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344:119–130PubMedCrossRefGoogle Scholar
  33. Hansen TH, Bouvier M (2009) MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 9:503–513PubMedCrossRefGoogle Scholar
  34. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344–362PubMedCrossRefGoogle Scholar
  35. Hu H, Cohen JI (2005) Varicella-zoster virus open reading frame 47 (ORF47) protein is critical for virus replication in dendritic cells and for spread to other cells. Virology 337:304–311PubMedCrossRefGoogle Scholar
  36. Huch J, Cunningham A, Arvin A, Nasr N, Santegoets S, Slobedman E, Slobedman B, Abendroth A (2010) Impact of varicella zoster virus on dendritic cell subsets in human skin during natural infection. J Virol 84:4060–4072Google Scholar
  37. Ihara T, Starr SE, Ito M, Douglas SD, Arbeter AM (1984) Human polymorphonuclear leukocyte-mediated cytotoxicity against varicella-zoster virus-infected fibroblasts. J Virol 51:110–116PubMedGoogle Scholar
  38. Ito M, Watanabe M, Kamiya H, Sakurai M (1996) Inhibition of natural killer (NK) cell activity against varicella-zoster virus (VZV)-infected fibroblasts and lymphocyte activation in response to VZV antigen by nitric oxide-releasing agents. Clin Exp Immunol 106:40–44PubMedCrossRefGoogle Scholar
  39. Jones JO, Arvin AM (2005) Viral and cellular gene transcription in fibroblasts infected with small plaque mutants of varicella-zoster virus. Antiviral Res 68:56–65PubMedCrossRefGoogle Scholar
  40. Jones JO, Arvin AM (2006) Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J Virol 80:5113–5124PubMedCrossRefGoogle Scholar
  41. Jura E, Chadwick EG, Josephs SH, Steinberg SP, Yogev R, Gershon AA, Krasinski KM, Borkowsky W (1989) Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J 8:586–590PubMedCrossRefGoogle Scholar
  42. Katze MG, He Y, Gale M Jr (2002) Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2:675–687PubMedCrossRefGoogle Scholar
  43. Klagge IM, Schneider-Schaulies S (1999) Virus interactions with dendritic cells. J Gen Virol 80:823–833PubMedGoogle Scholar
  44. Koppers-Lalic D, Reits EA, Ressing ME, Lipinska AD, Abele R, Koch J, Marcondes Rezende M, Admiraal P, van Leeuwen D, Bienkowska-Szewczyk K, Mettenleiter TC, Rijsewijk FA, Tampe R, Neefjes J, Wiertz EJ (2005) Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc Natl Acad Sci USA 102:5144–5149PubMedCrossRefGoogle Scholar
  45. Koppers-Lalic D, Verweij MC, Lipinska AD, Wang Y, Quinten E, Reits EA, Koch J, Loch S, Marcondes Rezende M, Daus F, Bienkowska-Szewczyk K, Osterrieder N, Mettenleiter TC, Heemskerk MH, Tampe R, Neefjes JJ, Chowdhury SI, Ressing ME, Rijsewijk FA, Wiertz EJ (2008) Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP. PLoS Pathog 4:e1000080PubMedCrossRefGoogle Scholar
  46. Koropchak CM, Solem SM, Diaz PS, Arvin AM (1989) Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol 63:2392–2395PubMedGoogle Scholar
  47. Koropchak CM, Graham G, Palmer J, Winsberg M, Ting SF, Wallace M, Prober CG, Arvin AM (1991) Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis 163:1016–1022PubMedCrossRefGoogle Scholar
  48. Ku CC, Padilla JA, Grose C, Butcher EC, Arvin AM (2002) Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol 76:11425–11433PubMedCrossRefGoogle Scholar
  49. Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM (2004) Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med 200:917–925, Epub 2004 Sep 27PubMedCrossRefGoogle Scholar
  50. Levin MJ, Hayward AR (1996) The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am 10:657–675PubMedCrossRefGoogle Scholar
  51. Liang L, Roizman B (2008) Expression of gamma interferon-dependent genes is blocked independently by virion host shutoff RNase and by US3 protein kinase. J Virol 82:4688–4696PubMedCrossRefGoogle Scholar
  52. Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275–306PubMedCrossRefGoogle Scholar
  53. Miller-Kittrell M, Sparer TE (2009) Feeling manipulated: cytomegalovirus immune manipulation. Virol J 6:4PubMedCrossRefGoogle Scholar
  54. Morrow G, Slobedman B, Cunningham AL, Abendroth A (2003) Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol 77:4950–4959PubMedCrossRefGoogle Scholar
  55. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M (1994) Functional role of type I and type II interferons in antiviral defense. Science 264:1918–1921PubMedCrossRefGoogle Scholar
  56. Nikkels AF, Debrus S, Sadzot-Delvaux C, Piette J, Rentier B, Pierard GE (1995) Localization of varicella-zoster virus nucleic acids and proteins in human skin. Neurology 45:S47–S49PubMedCrossRefGoogle Scholar
  57. Nikkels AF, Sadzot-Delvaux C, Pierard GE (2004) Absence of intercellular adhesion molecule 1 expression in varicella zoster virus-infected keratinocytes during herpes zoster: another immune evasion strategy? Am J Dermatopathol 26:27–32PubMedCrossRefGoogle Scholar
  58. Pober JS, Gimbrone MA Jr, Cotran RS, Reiss CS, Burakoff SJ, Fiers W, Ault KA (1983) Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. J Exp Med 157:1339–1353PubMedCrossRefGoogle Scholar
  59. Rothlein R, Dustin ML, Marlin SD, Springer TA (1986) A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137:1270–1274PubMedGoogle Scholar
  60. Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8:559–568PubMedCrossRefGoogle Scholar
  61. Salio M, Palmowski MJ, Atzberger A, Hermans IF, Cerundolo V (2004) CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J Exp Med 199:567–579PubMedCrossRefGoogle Scholar
  62. Schaap A, Fortin JF, Sommer M, Zerboni L, Stamatis S, Ku CC, Nolan GP, Arvin AM (2005) T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J Virol 79:12921–12933PubMedCrossRefGoogle Scholar
  63. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835–1837PubMedCrossRefGoogle Scholar
  64. Tomazin R, Hill AB, Jugovic P, York I, van Endert P, Ploegh HL, Andrews DW, Johnson DC (1996) Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J 15:3256–3266PubMedGoogle Scholar
  65. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL (2000) Viral subversion of the immune system. Annu Rev Immunol 18:861–926PubMedCrossRefGoogle Scholar
  66. Valladeau J, Saeland S (2005) Cutaneous dendritic cells. Semin Immunol 17:273–283PubMedCrossRefGoogle Scholar
  67. Verweij MC, Koppers-Lalic D, Loch S, Klauschies F, de la Salle H, Quinten E, Lehner PJ, Mulder A, Knittler MR, Tampe R, Koch J, Ressing ME, Wiertz EJ (2008) The varicellovirus UL49.5 protein blocks the transporter associated with antigen processing (TAP) by inhibiting essential conformational transitions in the 6+6 transmembrane TAP core complex. J Immunol 181:4894–4907PubMedGoogle Scholar
  68. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ (2008) Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41:206–212PubMedCrossRefGoogle Scholar
  69. Zhang Z, Wang FS (2005) Plasmacytoid dendritic cells act as the most competent cell type in linking antiviral innate and adaptive immune responses. Cell Mol Immunol 2:411–417PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Allison Abendroth
    • 1
    • 2
    Email author
  • Paul R. Kinchington
    • 3
    • 4
  • Barry Slobedman
    • 2
  1. 1.Department of Infectious Diseases and ImmunologyUniversity of SydneyCamperdownAustralia
  2. 2.Centre for Virus ResearchWestmead Millennium InstituteWestmeadAustralia
  3. 3.Department of Ophthalmology, School of MedicineUniversity of PittsburghPittsburghUSA
  4. 4.Department of Molecular Microbiology and Genetics, School of MedicineUniversity of PittsburghPittsburghUSA

Personalised recommendations